Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer

Giulia Marvaso,1,2,* Stefania Volpe,1,2,* Matteo Pepa,1,* Mattia Zaffaroni,1,* Giulia Corrao,1,2,* Matteo Augugliaro,1,* Franco Nolè,3,* Ottavio De Cobelli,2,4,* Barbara Alicja Jereczek-Fossa1,2,* 1Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy; 2Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; 3Medical Oncology Division of Urogenital & Head & Neck Tumors, IEO European Institute of Oncology IRCCS, Milan, Italy; 4Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy*These authors contributed equally to this workCorrespondence: Matteo PepaDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, ItalyEmail matteo.pepa@ieo.itAbstract: After primary treatment for prostate cancer with either radical prostatectomy or radiotherapy, a significant proportion of patients are at risk of developing metastases. In recent years, a deeper understanding of the underlying biology together with improved imaging techniques and the advent of new therapeutic options including metastases-directed therapies and new drugs have revolutionized the management of low-burden metastatic disease, also known as oligometastatic state. The purpose of this narrative review is to report the recent developments in the management of hormone-sensitive oligometastatic prostate cancer patients.Keywords: oligometastatic prostate cancer, metastasis-directed therapies, narrative review, imaging, biology